Elena Sotillo

May 15, 2024 | nature.com | Sean A. Yamada-Hunter |Brianna J. McIntosh |Frank Lin |Amaury Leruste |Zinaida Good |Calvin J Kuo | +6 more

AbstractAdoptively transferred T cells and agents designed to block the CD47–SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system1,2. Here we administered anti-CD47 antibodies in combination with adoptively transferred T cells with the goal of enhancing antitumour efficacy but observed abrogated therapeutic benefit due to rapid macrophage-mediated clearance of T cells expressing chimeric antigen receptors (CARs) or engineered T cell receptors.

Apr 23, 2024 | nature.com | Katherine Mueller |Andy Chen |Yingshi Chen |Bence Daniel |Jose Arias-Umana |Alice Wang | +10 more

Correction to: Nature https://doi.org/10.1038/s41586-024-07300-8 Published online 10 April 2024In the version of the article initially published, in the black violin plots in Fig. 5a, a dashed line was used to represent the mean and dotted lines for quartiles. This has now been corrected to a solid line for the mean and dashed lines for the quartiles in the HTML and PDF versions of the article.

Apr 10, 2024 | nature.com | Katherine Mueller |Andy Chen |Yingshi Chen |Bence Daniel |Jose Arias-Umana |Alice Wang | +10 more

AbstractA major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo1. The expression of memory-associated genes in CAR T cells is linked to their long-term persistence in patients and clinical efficacy2,3,4,5,6, suggesting that memory programs may underpin durable CAR T cell function. Here we show that the transcription factor FOXO1 is responsible for promoting memory and restraining exhaustion in human CAR T cells.

Mar 8, 2023 | nature.com | Won-Ju Kim |Caleb A Lareau |Elena Sotillo |Yajie Yin |Alexander Dunn |Ansuman T. Satpathy | +2 more

AbstractAlthough chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development for solid tumours because most target antigens are shared with normal cells1,2. Researchers have attempted to apply Boolean-logic gating to CAR T cells to prevent toxicity3,4,5; however, a truly safe and effective logic-gated CAR has remained elusive6.